Stocks That Hit 52-Week Lows On Thursday
During Thursday's session, 108 stocks hit new 52-week highs.
Looking Into Neurocrine Biosciences’s Return On Capital Employed
According to Benzinga Pro, during Q3, Neurocrine Biosciences (NASDAQ:NBIX) earned $68.50 million, a 505.33% increase from the preceding quarter. Neurocrine Biosciences also posted a total of $387.90 million in sales, a 2.56% increase since Q2.
JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $143
JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $138 to $143.
SVB Leerink Maintains Market Perform on Neurocrine Biosciences, Raises Price Target to $115
SVB Leerink analyst Marc Goodman maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Market Perform and raises the price target from $100 to $115.
Neurocrine Biosciences Buys UK-Based Hormone Therapy Player
Neurocrine Biosciences Inc (NASDAQ:NBIX) has agreed to pay £48.3 million for the U.K. hormone therapy group, Diurnal Group Plc. The 27.5p share…
Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance
Tucked in its Q2 earning release, Neurocrine Biosciences Inc (NASDAQ:NBIX) said that in August, the Phase 2a study of NBI-827104…
Neurocrine Biosciences Q2 EPS $0.84 Beats $0.59 Estimate, Sales $378.20M Beat $341.31M Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.59 by 42.37 percent. This is a 33.33 percent increase over earnings of $0.63 per share
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Morgan Stanley Maintains Equal-Weight on Neurocrine Biosciences, Raises Price Target to $102
Morgan Stanley analyst Jeffrey Hung maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Equal-Weight and raises the price target from $100 to $102.
Needham Previews Neurocrine’s Upcoming Mid-Stage Data from Essential Tremor Study
Needham previews the upcoming Phase 2 data readout for Neurocrine Biosciences Inc's (NASDAQ: NBIX) NBI-827104, a t-type calcium channel blocker in essential tremor (ET), by mid-2022.